F Edit Us28106w1036 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301  First clinical use of Editas-engineered. | July 27, 2022

United statesUnited kingdomGilmore oneillCristi barnettRon moldaverExchange commissionEditas medicine incDrug administrationBroad institute casGlobenewswire incEditas engineered ascasGilmoreo neillBroad institutePrivate securities litigation reform actAnnual reportEditas medicine